Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
Collection
For ¥0.57 per day, unlimited downloads CREATE MEMBERSHIP Download

toTop

If you have any feedback, Please follow the official account to submit feedback.

Turn on your phone and scan

home > search >

The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer

Author:
Cooperberg, Matthew R.  Erho, Nicholas  Chan, June M.  Feng, Felix Y.  Fishbane, Nick  Zhao, Shuang G.  Simko, Jeffry P.  Cowan, Janet E.  Lehrer, Jonathan  Alshalalfa, Mohammed  Kolisnik, Tyler  Chelliserry, Jijumon  Margrave, Jennifer  Aranes, Maria  du Plessis, Marguerite  Buerki, Christine  Tenggara, Imelda  Davicioni, Elai  Carroll, Peter R.  


Journal:
EUROPEAN UROLOGY


Issue Date:
2018


Abstract(summary):

Background: Among men with clinically low-risk prostate cancer, we have previously documented heterogeneity in terms of clinical characteristics and genomic risk scores. Objective: To further study the underlying tumor biology of this patient population, by interrogating broader patterns of gene expression among men with clinically low-risk tumors. Design, setting, and participants: Prostate biopsies from 427 patients considered potentially suitable for active surveillance underwent central pathology review and genome-wide expression profiling. These cases were compared with 1290 higher-risk biopsy cases with diverse clinical features from a prospective genomic registry. Outcome measurements and statistical analysis: Average genomic risk (AGR) was determined from 18 published prognostic signatures, and MSigDB hallmark gene sets were analyzed using boot-strapped clustering methods. These sets were examined in relation to clinical variables and pathological and biochemical outcomes using multivariable regression analysis. Results and limitations: A total of 408 (96%) biopsies passed RNA quality control. Based on AGR quartiles defined by the high-risk multicenter cases, the University of California, San Francisco (UCSF) low-risk patients were distributed across the quartiles as 219 (54%), 107 (26%), 61 (15%), and 21 (5%). Unsupervised clustering analysis of the hallmark gene set scores revealed three clusters, which were enriched for the previously described PAM50 luminal A, luminal B, and basal subtypes. AGR, but not the clusters, was associated with both pathological (odds ratio 1.34, 95% confidence interval [CI] 1.14-1.58) and biochemical outcomes (hazard ratio 1.53, 95% CI 1.19-1.93). These results may underestimate within-prostate genomic heterogeneity. Conclusions: Prostate cancers that are homogeneously low risk by traditional characteristics demonstrate substantial diversity at the level of genomic expression. Molecular substratification of lowrisk prostate cancer will yield a better understanding of its divergent biology and, in the future may help personalize treatment recommendations. Patient summary: We studied the genomic characteristics of tumors from men diagnosed with lowrisk prostate cancer. We found three main subtypes of prostate cancer with divergent tumor biology, similar to what has previously been found in women with breast cancer. In addition, we found that genomic risk scores were associated with worse pathology findings and prostate-specific antigen recurrence after surgery. These results suggest even greater genomic diversity among low-risk patients than has previously been documented with more limited signatures. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.


Page:
444---452


VIEW PDF

The preview is over

If you wish to continue, please create your membership or download this.

Create Membership

Similar Literature

Submit Feedback

This function is a member function, members do not limit the number of downloads